{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:55:48Z","timestamp":1791442548448,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104940","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:46:37Z","timestamp":1790869597000},"page":"104940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare system"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-623X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mattar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Pimentel","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Francisco","family":"Correa-Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Baldassin","family":"Pavanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia S. Kurokawa","family":"La Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Klarmann","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2026.104940_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.breast.2026.104940_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10549-020-05831-y","article-title":"The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)","volume":"183","author":"Rosa","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104940_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.breast.2019.01.008","article-title":"Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: the AMAZONA retrospective cohort study","volume":"44","author":"Simon","year":"2019","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2026.104940_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"33","key":"10.1016\/j.breast.2026.104940_bib6","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9897","key":"10.1016\/j.breast.2026.104940_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104940_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS15-S5-04","volume":"76","author":"Slamon","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104940_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104940_bib10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105112","article-title":"Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3 years' median follow-up","volume":"10","author":"Loibl","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.breast.2026.104940_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-Positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"10195","key":"10.1016\/j.breast.2026.104940_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(19)31243-7","article-title":"Brazil's unified health system: the first 30 years and prospects for the future","volume":"394","author":"Castro","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104940_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/GO.20.00566","article-title":"Challenge of incorporating new drugs for breast cancer in Brazil: a proposed framework for improving access to innovative therapies","volume":"7","author":"Barrios","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib15","article-title":"Inequalities in unmet need for health care services and medications in Brazil: a decomposition analysis","volume":"19","author":"Coube","year":"2023","journal-title":"Lancet Reg Health, Am"},{"key":"10.1016\/j.breast.2026.104940_bib16","doi-asserted-by":"crossref","DOI":"10.1590\/s2237-96222024v33e20240057.en","article-title":"Health technology assessment in the Brazilian National health System: profile of CONITEC exclusion recommendations, 2012-2023","volume":"33","author":"Pinheiro","year":"2024","journal-title":"Epidemiol Serv Saude"},{"key":"10.1016\/j.breast.2026.104940_bib17","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas: C\u00e2ncer de Mama","year":"2024"},{"issue":"Suppl 2","key":"10.1016\/j.breast.2026.104940_bib18","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jval.2019.04.257","article-title":"Pertuzumab plus trastuzumab on the neoadjuvant treatment of her2-positive breast cancer: a cost analysis of recurrent disease on the brazilian public healthcare system","volume":"22","author":"Kashiura","year":"2019","journal-title":"Value Health"},{"issue":"Suppl 16","key":"10.1016\/j.breast.2026.104940_bib19","article-title":"The worldwide impact of HER2-targeted treatments in women with breast cancer: an epidemiological modeling study","volume":"41","author":"Press","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib20","series-title":"Avoidable mortality: oecd\/eurostat lists of preventable and treatable causes of death (January 2022 version)","year":"2022"},{"issue":"1","key":"10.1016\/j.breast.2026.104940_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canep.2014.11.002","article-title":"Understanding the impact of socioeconomic differences in breast cancer survival in England and Wales: avoidable deaths and potential gain in expectation of life","volume":"39","author":"Rutherford","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.breast.2026.104940_bib22","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/S2214-109X(25)00494-2","article-title":"Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study","volume":"14","author":"Langselius","year":"2026","journal-title":"Lancet Glob Health"},{"issue":"31","key":"10.1016\/j.breast.2026.104940_bib23","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-Positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update","volume":"42","author":"Loibl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104940_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.breast.2026.104940_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JGO.2016.005678","article-title":"Estimation of premature deaths from lack of access to Anti-HER2 therapy for advanced breast cancer in the Brazilian public health System","volume":"3","author":"Debiasi","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib26","first-page":"PCN33","article-title":"Pertuzumab+trastuzumab treatment on her2+ early breast cancer: long-term reduction of metastasic breast cancer incidence in Argentina","volume":"19","author":"Penayo","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"12","key":"10.1016\/j.breast.2026.104940_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40261-024-01399-3","article-title":"Cost-Effectiveness analysis of adjuvant pertuzumab and trastuzumab in human epidermal growth factor receptor 2-Positive early breast cancer in Japan","volume":"44","author":"Nusawat","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.breast.2026.104940_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000816","article-title":"Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States","volume":"44","author":"Sussell","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib29","doi-asserted-by":"crossref","first-page":"eGS6655","DOI":"10.31744\/einstein_journal\/2022GS6655","article-title":"Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer","volume":"20","author":"Magalhaes Filho","year":"2022","journal-title":"Einstein (Sao Paulo)"},{"issue":"4","key":"10.1016\/j.breast.2026.104940_bib30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jval.2018.11.014","article-title":"Cost-Effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-Positive breast cancer in the United States","volume":"22","author":"Garrison","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104940_bib31","series-title":"Censo Demogr\u00e1fico 2022","year":"2022"},{"key":"10.1016\/j.breast.2026.104940_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.927748","article-title":"Breast cancer survival and the health system in Brazil: an analysis of public and private healthcare","volume":"13","author":"Ferreira","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104940_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1169982","article-title":"Discrepancies in breast cancer's oncological outcomes between public and private institutions in the southeast region of Brazil: a retrospective cohort study","volume":"13","author":"Andrade","year":"2023","journal-title":"Front Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:47:25Z","timestamp":1791442045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"alternative-id":["S096097762600250X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104940","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare system","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104940"}}